IOM to Advise FDA on Post-Marketing Drug Safety Trials
The Institute of Medicine has been called upon to advise the FDA regarding post-marketing drug safety trials. George Conk at Otherwise has the details.
–CJR
Posted in:
Editor: Christopher J. Robinette